1.Developing a curriculum framework for vocational competency in college students with disabilities:based on RCF and ICF
Shan GUAN ; Meili SUN ; Yi GUAN ; Yifan XUE ; Yuliang ZHONG ; Xinqin LI
Chinese Journal of Rehabilitation Theory and Practice 2025;31(4):415-422
Objective To develop a professional competency-oriented higher education curriculum system for college students with disabilities based on rehabilitation competency framework(RCF)and International Classification of Functioning,Disability and Health(ICF).Methods A framework for a professional competency-oriented higher education curriculum system for college students with disabilities was developed following the principles of systematic curriculum design.The curriculum design was student-centered and adhered to principles such as inclusive education,competency-based learning,lifelong career development and collaborative cooperation.It emphasized the application of digital empowerment technol-ogies,accessibility technologies and assistive technologies.Results The curriculum system framework comprised six core curriculum domains,including knowledge,skills,profes-sional mindset and values,management and leadership,professionalism and behavior,functional adaptation and digital empowerment,as well as accessibility and assistive technology applications.The curriculum modules were structured into four stages,including adaptation and functional enhancement,career exploration and founda-tional skill development,professional skill enhancement and workplace practice,and employment guidance and follow-up services.This curriculum system systematically enhanced the professional knowledge,skills and com-petencies of college students with disabilities,integrating digital empowerment strategies to support their career development.Conclusion The competency-oriented higher education curriculum system constructed based on RCF and ICF provides a theoretical framework and practical pathway for improving the professional competency and lifelong career de-velopment of college students with disabilities.
2.Developing a curriculum framework for vocational competency in college students with disabilities:based on RCF and ICF
Shan GUAN ; Meili SUN ; Yi GUAN ; Yifan XUE ; Yuliang ZHONG ; Xinqin LI
Chinese Journal of Rehabilitation Theory and Practice 2025;31(4):415-422
Objective To develop a professional competency-oriented higher education curriculum system for college students with disabilities based on rehabilitation competency framework(RCF)and International Classification of Functioning,Disability and Health(ICF).Methods A framework for a professional competency-oriented higher education curriculum system for college students with disabilities was developed following the principles of systematic curriculum design.The curriculum design was student-centered and adhered to principles such as inclusive education,competency-based learning,lifelong career development and collaborative cooperation.It emphasized the application of digital empowerment technol-ogies,accessibility technologies and assistive technologies.Results The curriculum system framework comprised six core curriculum domains,including knowledge,skills,profes-sional mindset and values,management and leadership,professionalism and behavior,functional adaptation and digital empowerment,as well as accessibility and assistive technology applications.The curriculum modules were structured into four stages,including adaptation and functional enhancement,career exploration and founda-tional skill development,professional skill enhancement and workplace practice,and employment guidance and follow-up services.This curriculum system systematically enhanced the professional knowledge,skills and com-petencies of college students with disabilities,integrating digital empowerment strategies to support their career development.Conclusion The competency-oriented higher education curriculum system constructed based on RCF and ICF provides a theoretical framework and practical pathway for improving the professional competency and lifelong career de-velopment of college students with disabilities.
3.Investigation and analysis of the current situation of case reporting ethical review and patient informed consent reports in comprehensive journals of clinical medicine in China
Yue CAO ; Yuliang GUI ; Yan YANG ; Le ZHOU ; Wenqi BAO ; Lumin ZHOU ; Qiaoni ZHONG ; Jingyi XIAN ; Di HUANG
Chinese Medical Ethics 2024;37(5):520-525
Objective:To investigate and analyze case reporting ethical review and patient informed consent reports published in the comprehensive journals of clinical medicine in China in 2022.Methods:According to the data from the 2022 Edition of the Chinese Science and Technology Journal of the Citation Reports(Extended Version),the case reports published in comprehensive journals of clinical medicine in 2022 were selected as the research objects.The information on ethics and patient informed consent was extracted from the case reports that met the selection criteria,and Microsoft Excel 2021 and SPSS 21.0 were used to sort out and analyze the data.Results:A total of 587 case reporting articles were published in the 42 included journals in 2022,of which 36(6.13%)reported on science and technology ethics and/or informed consent.Case reports reporting on science and technology ethics and/or informed consent mostly came from the key magazine of China technology(88.89%Vs.65.88%),and the proportion of manuscripts involving science and technology ethics on the official website of the journal was relatively high(86.11%Vs.63.88%),and the difference was statistically significant(P<0.01).Conclusion:The proportion of case reports of science and technology ethics and/or informed consent in journals of comprehensive discipline classification of clinical medicine was relatively low.Currently,most international journals are required to obtain the informed consent of patients or legal guardians before publishing case reports.Compared with this,there are still certain gaps in China,which need to be paid great attention to.
4.Sequencing and analysis of the whole genome of a strain of rabies virus transmitted by hog badger in Sichuan province
Hongrong ZHONG ; Mingfeng JIANG ; Yuliang FENG ; Xingyu ZHOU ; Wei LI
Chinese Journal of Experimental and Clinical Virology 2024;38(3):286-293
Objective:The objective of this study is to sequence whole genome of the rabies virus in the saliva specimen of a suspected rabies case with onset of rabies from a wildlife (hog badger) bite wound in Sichuan province, where the genetic variation characteristics of the virus was analyzed at the molecular level, so as to understand the prevalence and mutation of wildlife rabies virus in Sichuan province.Methods:Total viral RNA was extracted from the saliva specimen of the suspected rabies case. Then, rabies virus sequences were amplified using PCR with specific primers; the gene fragments obtained were sequenced, and the sequences obtained were spliced using biological software to obtain the whole genome sequence of the rabies virus strain. The genetic variation characteristics of the whole genome were analyzed.Results:The whole genome nucleotide sequence of a strain of rabies virus of hog badger origin (hereinafter referred to as SCR23-052) was obtained by sequencing, and NCBI online BLAST and comparison with several reference sequences showed that the composition and structure of the whole genome sequence of SCR23-052 conformed to the characteristics of the Lyssavirus under the Rhabdoviridae; the highest similarity in nucleotide and amino acid sequences in various gene regions was observed between SCR23-052 and the strains of Ningxia (J) and Chongqing (CQ92, 02050CHI). The sequence variability of SCR23-052 genome was significantly lower at the amino acid level than that at the nucleotide level, which indicated that most of the nucleotide variants in the protein-coding genes belonged to synonymous mutations. Phylogenetic analysis showed that SCR23-052 belonged to genotype V, which did not show any obvious mutation in the major antigenic site of the glycoprotein, underwent amino acid glycosylation at positions 56 and 338 by the online site prediction, and showed the least amino acid difference compared with the signal peptide sequence of the vaccine strain CTN181. The virus in this study has an A→T mutation at position 332 in the nucleoprotein major antigenic site with all reference vaccine strains, and an L→V mutation at position 379 in the B-cell epitope with the CTN181 vaccine strain. SCR23-052 was consistent with both genotype V reference strains at the nucleoprotein study site.Conclusions:The whole genome sequence of a wildlife strain of genotype V rabies virus of hog badger origin was obtained, which was different from that of the genotype I strain of rabies virus of dog origin that previously reported to be prevalent in Sichuan. The genome sequence of SCR23-052 differed from that of the reference vaccine strains to a varying degree, but the main virulence characteristics remained unaltered.
5.Molecular biological characterization analysis of the first imported case of Zika virus disease in Sichuan province of China
Wei LI ; Lvbo TIAN ; Hongrong ZHONG ; Mingfeng JIANG ; Zhenhua CHEN ; Qing ZHANG ; Xingyu ZHOU ; Ming PAN ; Yuliang FENG
Chinese Journal of Experimental and Clinical Virology 2024;38(6):649-654
Objective:To detect and study the genetic evolution and biological characteristics of the first imported Zika virus (ZIKV) in a suspected case from Singapore to Sichuan Tianfu airport for inbound transfer on June 28, 2024, and so to provide reference for prevention and control of ZIKV disease.Methods:Serum sample was collected from the inbound transfer passenger, we detected ZIKV RNA using real-time RT-PCR method. The whole genome sequence was obtained through target next-generation sequencing (tNGS). CLC Genomics Workbench software was used for sequence analysis and splicing, and MEGA 7.0 software was used for phylogenetic tree construction.Results:Real-time RT-PCR result showed that the serum sample was positive. The phylogenetic tree which was constructed based on the whole genome sequence of ZIKV indicated the Sichuan strain was located on Asian lineage. Gene homology analysis showed that the homology between Sichuan strain and Asian, African strains ranged from 84.4%-98.6%. The Sichuan strain showed unique molecular features of 139S, 982V and 2634M.Conclusions:The ZIKV strain in Sichuan inbound transfer passenger in June 2024 belongs to the Asian lineage, which agrees with the epidemiological investigation outcome.
6.Molecular biological characterization analysis of the first imported case of Zika virus disease in Sichuan province of China
Wei LI ; Lvbo TIAN ; Hongrong ZHONG ; Mingfeng JIANG ; Zhenhua CHEN ; Qing ZHANG ; Xingyu ZHOU ; Ming PAN ; Yuliang FENG
Chinese Journal of Experimental and Clinical Virology 2024;38(6):649-654
Objective:To detect and study the genetic evolution and biological characteristics of the first imported Zika virus (ZIKV) in a suspected case from Singapore to Sichuan Tianfu airport for inbound transfer on June 28, 2024, and so to provide reference for prevention and control of ZIKV disease.Methods:Serum sample was collected from the inbound transfer passenger, we detected ZIKV RNA using real-time RT-PCR method. The whole genome sequence was obtained through target next-generation sequencing (tNGS). CLC Genomics Workbench software was used for sequence analysis and splicing, and MEGA 7.0 software was used for phylogenetic tree construction.Results:Real-time RT-PCR result showed that the serum sample was positive. The phylogenetic tree which was constructed based on the whole genome sequence of ZIKV indicated the Sichuan strain was located on Asian lineage. Gene homology analysis showed that the homology between Sichuan strain and Asian, African strains ranged from 84.4%-98.6%. The Sichuan strain showed unique molecular features of 139S, 982V and 2634M.Conclusions:The ZIKV strain in Sichuan inbound transfer passenger in June 2024 belongs to the Asian lineage, which agrees with the epidemiological investigation outcome.
7.Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail
Nan CHEN ; Changying XING ; Jianying NIU ; Bicheng LIU ; Junzhou FU ; Jiuyang ZHAO ; Zhaohui NI ; Mei WANG ; Wenhu LIU ; Jinghong ZHAO ; Ling ZHONG ; Xiongfei WU ; Wenge LI ; Yuqing CHEN ; Wei SHI ; Jianghua CHEN ; Aiping YIN ; Ping FU ; Rong WANG ; Gengru JIANG ; Fanfan HOU ; Guohua DING ; Jing CHEN ; Gang XU ; Yuichiro KONDO ; Yuliang SU ; Changlin MEI
Chronic Diseases and Translational Medicine 2022;08(1):59-70
Background::Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods::Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients ( n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group ( n = 56) and a twice or three times per week intravenous epoetin alfa group ( n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS? software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators. Results::The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion::Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.
8.Molecular characteristics analysis of imported dengue virus E gene in Sichuan province, China, 2012-2021
Wei LI ; Mingfeng JIANG ; Hongrong ZHONG ; Yiou CAO ; Yuliang FENG
Chinese Journal of Experimental and Clinical Virology 2022;36(5):586-590
Objective:To analyze the molecular characteristics of E genes of imported dengue virus (DENV) in Sichuan province from 2012 to 2021, such as serotypes and genotypes, and so to provide the basis for virus traceability.Methods:DENV E genes of the 28 serum samples which were tested DENV positive by real time RT-qPCR from 2012 to 2021 in Sichuan province were amplified and sequenced by RT-PCR. Bioinformatics software Mega Align5.0 was used for the alignment analyses of nucleotide and deduced amino acid sequences, and bioinformatics software Mega7.0 was used to draw phylogenetic trees.Results:RT-PCR and sequencing indicated that 28 E genes of DENV were obtained. The serotypes and genotypes of DENV were revealed by homology and phylogenetic analysis based on E genes of DENV; 20 virus strains of Sichuan belonged to DENV serotype 1 (DENV-1), of which 16 virus strains were genotype I (G-I), 4 virus strains were genotype V (G-V); 7 virus strains belonged to DENV serotype 2 (DENV-2), of which 4 virus strains were G-I, 3 virus strains were genotype II (G-II); 1 virus strain belonged to DENV serotype 3 (DENV-3), G-I. The phylogenetic trees showed that Sichuan strains had more homology with strains of Southeast Asia and Guangdong province in China, that is consistent with the epidemiological data.Conclusions:In 2012 to 2021, the imported DENV in Sichuan province had 3 serotypes and multiple genotypes, and they were most likely transmitted from Southeast Asian countries.
9.Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail
Nan CHEN ; Changying XING ; Jianying NIU ; Bicheng LIU ; Junzhou FU ; Jiuyang ZHAO ; Zhaohui NI ; Mei WANG ; Wenhu LIU ; Jinghong ZHAO ; Ling ZHONG ; Xiongfei WU ; Wenge LI ; Yuqing CHEN ; Wei SHI ; Jianghua CHEN ; Aiping YIN ; Ping FU ; Rong WANG ; Gengru JIANG ; Fanfan HOU ; Guohua DING ; Jing CHEN ; Gang XU ; Yuichiro KONDO ; Yuliang SU ; Changlin MEI
Chronic Diseases and Translational Medicine 2022;08(1):59-70
Background::Erythropoietin is a glycoprotein that mainly regulates erythropoiesis. In patients with chronic renal failure with anemia, darbepoetin alfa can stimulate erythropoiesis, correct anemia, and maintain hemoglobin levels. This study was designed to demonstrate the efficacy and safety of darbepoetin alfa injections as being not inferior to epoetin alfa injections (Recombinant Human Erythropoietin injection, rHuEPO) when maintaining hemoglobin (Hb) levels within the target range (10.0-12.0 g/dL) for the treatment of renal anemia.Methods::Ninety-five patients were enrolled in this study from April 15, 2013 to April 10, 2014 at 25 sites. In this study, patients ( n = 95) aged 18-70 years were randomized into a once per week intravenous darbepoetin alfa group ( n = 56) and a twice or three times per week intravenous epoetin alfa group ( n = 39) for 28 weeks, who had anemia with hemoglobin levels between 6 g/dL and 10 g/dL due to chronic kidney disease (CKD) and were undergoing hemodialysis or hemofiltration with ESA-naive (erythropoiesis stimulating agent-naive). The primary efficacy profile was the mean Hb level (the non-inferiority margin was -1.0 g/dL, week 21-28); the secondary efficacy profiles were the Hb increase rate (week 0-4), the target Hb achievement cumulative rate and time, the change trends of the Hb levels, and the target Hb maintenance ratio. Adverse events (AEs) were observed and compared, and the efficacy and safety were analyzed between the two treatment groups. Additionally, the frequencies of dose adjustments between the darbepoetin alfa and epoetin alfa groups were compared during the treatment period. SAS? software version 9.2 was used to perform all statistical analyses. Descriptive statistics were used for all efficacy, safety, and demographic variable analyses, including for the primary efficacy indicators. Results::The mean Hb level was 11.3 g/dL in the darbepoetin alfa group and 10.7 g/dL in the epoetin alfa group, respectively; the difference of the lower limits of the 95% confidence intervals (CI) between the two groups was 0.1 g/dL (>-1.0 g/dL), and non-inferiority was proven; the Hb levels started to increase in the first four weeks at a similar increase rate; no obvious differences were observed between the groups in the target Hb achievement cumulative rates, and the Hb levels as well as the target Hb level maintenance rate changed over time. The incidence of AEs was 62.5% in the darbepoetin alfa group and 76.9% in the epoetin alfa group. All the adverse events observed in the study were those commonly associated with hemodialysis.Conclusion::Darbepoetin alfa intravenously once per week can effectively increase Hb levels and maintain the target Hb levels well, which makes it not inferior to epoetin alfa intravenously twice or three times per week. Darbepoetin alfa shows an efficacy and safety comparable to epoetin alfa for the treatment of renal anemia.
10.Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition).
Xin YE ; Weijun FAN ; Zhongmin WANG ; Junjie WANG ; Hui WANG ; Jun WANG ; Chuntang WANG ; Lizhi NIU ; Yong FANG ; Shanzhi GU ; Hui TIAN ; Baodong LIU ; Lou ZHONG ; Yiping ZHUANG ; Jiachang CHI ; Xichao SUN ; Nuo YANG ; Zhigang WEI ; Xiao LI ; Xiaoguang LI ; Yuliang LI ; Chunhai LI ; Yan LI ; Xia YANG ; Wuwei YANG ; Po YANG ; Zhengqiang YANG ; Yueyong XIAO ; Xiaoming SONG ; Kaixian ZHANG ; Shilin CHEN ; Weisheng CHEN ; Zhengyu LIN ; Dianjie LIN ; Zhiqiang MENG ; Xiaojing ZHAO ; Kaiwen HU ; Chen LIU ; Cheng LIU ; Chundong GU ; Dong XU ; Yong HUANG ; Guanghui HUANG ; Zhongmin PENG ; Liang DONG ; Lei JIANG ; Yue HAN ; Qingshi ZENG ; Yong JIN ; Guangyan LEI ; Bo ZHAI ; Hailiang LI ; Jie PAN
Chinese Journal of Lung Cancer 2021;24(5):305-322
"The Expert Group on Tumor Ablation Therapy of Chinese Medical Doctor Association, The Tumor Ablation Committee of Chinese College of Interventionalists, The Society of Tumor Ablation Therapy of Chinese Anti-Cancer Association and The Ablation Expert Committee of the Chinese Society of Clinical Oncology" have organized multidisciplinary experts to formulate the consensus for thermal ablation of pulmonary subsolid nodules or ground-glass nodule (GGN). The expert consensus reviews current literatures and provides clinical practices for thermal ablation of GGN. The main contents include: (1) clinical evaluation of GGN, (2) procedures, indications, contraindications, outcomes evaluation and related complications of thermal ablation for GGN and (3) future development directions.
.

Result Analysis
Print
Save
E-mail